Pulmicort and Qnasl drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Pulmicort (budesonide) and Qnasl (beclomethasone dipropionate). Common drug interactions include sinusitis among females and loss of consciousness among males.

The phase IV clinical study analyzes what interactions people have when they take Pulmicort and Qnasl. It is created by eHealthMe based on reports of 55 people who take the same drugs from the FDA, and is updated regularly.

What is Pulmicort?

Pulmicort has active ingredients of budesonide. It is often used in asthma. eHealthMe is studying from 34,980 Pulmicort users. Check the latest studies of Pulmicort.

What is Qnasl?

Qnasl has active ingredients of beclomethasone dipropionate. It is often used in allergies. eHealthMe is studying from 1,984 Qnasl users. Check the latest studies of Qnasl.

On Jul, 20, 2026

55 people who take Pulmicort and Qnasl together, and have interactions are studied.

What are the common drug interactions of Pulmicort and Qnasl, by gender? *:

female:

Sinusitis (inflammation of sinus)
Chronic sinusitis (long lasting inflammation of the paranasal sinuses)
Tooth infection
Cat scratch disease (bacterial infection by cat scratch)
Lyme disease (a bacterial infection that is spread to humans by infected ticks)
Malaise (a feeling of general discomfort or uneasiness)
Poor venous access
Sialoadenitis (inflammation of a salivary gland)
Sinus disorder (disease of sinus)
Staphylococcal infection (an infection with staphylococcus bacteria)

male:

Loss of consciousness
Sinusitis (inflammation of sinus)
Facial bones fracture (bone fracture of face)
Fall
Swelling
Tooth fracture
Drug ineffective
Rash pruritic (redness with itching)
Hypertension (high blood pressure)
Malaise (a feeling of general discomfort or uneasiness)

What are the common drug interactions of Pulmicort and Qnasl, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Injection site erythema (redness at injection site)
Injection site swelling
Injection site urticaria (rash of round, red welts on the skin at injection site)
Pruritus generalised (generalized itching)

10-19:

Drug ineffective
Sinusitis (inflammation of sinus)
Lung disorder (lung disease)
Pharyngitis streptococcal (inflammation of the pharynx caused by infection from. streptococcus)

20-29:

Electrocardiogram qt prolonged

30-39:

Pharyngitis streptococcal (inflammation of the pharynx caused by infection from. streptococcus)
Pyrexia (fever)
Sinusitis (inflammation of sinus)

40-49:

Somnolence (a state of near-sleep, a strong desire for sleep)
Suicidal ideation
Allergy to plants
Loss of consciousness
Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
Nausea (feeling of having an urge to vomit)
Respiration (transport of oxygen from the outside air to the cells within tissues)
Stent placement
Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
Food poisoning (poison in food)

50-59:

Application site discolouration
Bacterial infection
Cat scratch disease (bacterial infection by cat scratch)
Central nervous system infection (infection of brain or spinal cord)
Cerebrospinal fluid leakage
Chronic sinusitis (long lasting inflammation of the paranasal sinuses)
Infection
Intestinal obstruction
Lyme disease (a bacterial infection that is spread to humans by infected ticks)
Malaise (a feeling of general discomfort or uneasiness)

60+:

Rash pruritic (redness with itching)
Sinusitis (inflammation of sinus)
Device failure
Nasal polyps (masses that develop in the lining of the nose)
Mycobacterium fortuitum infection (bacterial infection)
Pneumonia
Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
Urinary retention (the inability to completely or partially empty the bladder)
Wheezing (a high-pitched whistling sound made while you breath)

What are the existing conditions these people have? *

Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 15 people, 27.27%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 13 people, 23.64%
Immunodeficiency: 11 people, 20.00%
Immunodeficiency Common Variable: 10 people, 18.18%
Combined Immunodeficiency: 3 people, 5.45%
Allergic Rhinitis: 3 people, 5.45%

* Approximation only. Some reports may have incomplete information.

Do you take Pulmicort and Qnasl?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously